2022年欧洲肿瘤内科学会（ESMO）BC大会将于5月3~5日（当地时间）正式召开，会上将报告转化研究、新药、分子和功能诊断、生物标志物以及临床研究中的前沿研究，提供所有改变临床实践新数据的全面概述，并确保其具有清晰的临床诊疗路线图。日前，会议已经正式公布口头报告日程，【肿瘤资讯】为您整理了相关口头报告及迷你口头报告专场内容，供大家学习参考。
口头报告专场
162O - DS8201-A-U105研究的初步分析：在HER2表达的晚期乳腺癌患者中，一项评估trastuzumab deruxtecan(T-DXd)与纳武利尤单抗(nivo)联用的开放性、1b期试验（2-part）
Primary analysis from DS8201-A-U105: A 2-part, open label, phase 1b trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer.
163O-在HER2阳性(HER2 +)转移性乳腺癌(MBC)患者中，比较T-DXd与T-DM1的随机、III期研究DESTINY-Breast03的患者报告结局(PRO)
Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (TDM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
164O-帕博利珠单抗(pembro)+ 化疗（化疗）与安慰剂(pbo)+ 化疗作为晚期三阴性乳腺癌(TNBC)一线治疗的健康相关生活质量(HRQoL)比较：KEYNOTE-355的结果
Health-Related Quality of Life (HRQoL) With Pembrolizumab (pembro) +Chemotherapy (chemo) vs Placebo (pbo) + Chemo as 1L Treatment for Advanced Triple-Negative Breast Cancer (TNBC): Results From KEYNOTE-355
161O-VIOLETTE：在转移性三阴性乳腺癌(mTNBC)患者中，奥拉帕利(ola)+ Ceralasertib(cer)或Adavosertib(ada) vs 奥拉帕利单药的随机、II期研究
VIOLETTE: Randomised Phase 2 Study of Olaparib (ola) + Ceralasertib (cer) or Adavosertib (ada) vs Ola Alone in Patients (pts) With Metastatic Triple-Negative Breast Cancer (mTNBC).
Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment.
迷你口头报告专场
59MO-阿贝西利联合内分泌(ET) 辅助治疗：monarchE研究队列1的疗效结果
Adjuvant Abemaciclib Combined with Endocrine Therapy (ET): Efficacy Results in monarchE Cohort 1
60MO-激素受体(HR)阳性、HER2阴性早期乳腺癌(BC)年轻患者，新辅助治疗后接受哌柏西利(PAL)和内分泌治疗(ET)的的卵巢功能：Penelope-B探索性分析
Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): explorative analysis in Penelope-B
91MO-乳腺癌试验组ANZ 1401 ELIMINATE试验：新辅助化疗联合或不联合芳香化酶抑制剂降期治疗ER+乳腺癌
Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials group ANZ 1401 ELIMINATE trial.
92MO- CheckMate 7A8研究：纳武利尤单抗(NIVO)+ 哌柏西利(PALBO)+ 阿那曲唑(ANA) 新辅助治疗雌激素受体阳性(ER +)/人表皮生长因子受体2阴性(HER2-)原发性乳腺癌(BC)
Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8.
93MO-PHERGain试验中，对于接受曲妥珠单抗(T)和帕妥珠单抗(P) 新辅助治疗的HER2阳性（HER2+）早期乳腺癌(EBC)患者(pts)，预测病理学完全缓解(pCR)的最佳18F-FDG PET/CT(FDG-PET)临界值
Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
165MO-德喜曲妥珠单抗(T-DXd)治疗HER2阳性活动性脑转移乳腺癌患者：TUXEDO-1试验的主要结局分析
Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
166MO-Datopotamab deruxtecan(Dato-DXd)+ 度伐利尤单抗(D)一线(1L)治疗不可切除的局部晚期/转移性三阴性乳腺癌(a/mTNBC)：BEGONIA（一项1b/2期研究）的初步结果
166MO - Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase 1b/2 study
167MO-ER、PR和HER2水平与哌柏西利(Pal)+ 芳香化酶抑制剂(AI)一线治疗ER + /HER2-转移性乳腺癌(MBC)的结局相关性：PADA-1试验的探索性分析
Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 Trial
Prognostic and biologic significance of HER2-low expression in early breast cancer
2MO-HER2阳性早期乳腺癌患者预后基因表达标记的开发
2MO - Development of a prognostic gene-expression signature for early stage HER2-positive breast cancer patients
3MO-基于HER2DX评分模型与早期三阴性乳腺癌(eTNBC)生存期的相关性
Association of the research-based HER2DX signatures with survival in early-stage triple-negative breast cancer (eTNBC)
具体日程请点击下方网址：
排版编辑：肿瘤资讯-Jo
苏公网安备32059002004080号
